肝细胞型胆汁淤积诊治进展

doi:10.3969/j.issn.1672-5069.2020.01.043

Abstract

Hu Lilin, Wang Weijun, Yang Ling. Diagnosis and treatment ofparenchymal jaundice:a type of cholestasis[J]. Journal of Practical Hepatology, 2020, 23(1): 156-160.

[1] Trauner M, Fuchs CD, Halilbasic E, et al. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology,2017,65(4):1393-1404.
[2] Cai SY, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight,2017,2(5):e90780.
[3] 蔡晓波,陆伦根. 胆汁淤积性肝病的“下降”病理生理学模式. 中华肝脏病杂志,2019,27(5):321-324.
[4] EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol,2019,70(6):1222-1261.
[5] Gijbels E, Vinken M. Mechanisms ofdrug-induced cholestasis. Methods Mol Biol,2019,1981:1-14.
[6] Jüngst C, Berg T, Cheng J, et al. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest,2013,43(10):1069-1083.
[7] Rossi RE, Conte D, Massironi S. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues. Dig Liver Dis,2015,47(10):819-825.
[8] 范建高, 徐正婕. 酒精性肝病和胆汁淤积. 肝脏,2000,3(1):34.
[9] Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol,2019,16(4):235-246.
[10] Brandl K, Hartmann P, Jih LJ, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol,2018,69(2):396-405.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[12] Lammert F, Marschall H-U, Glantz A, et al. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol,2000,33(6):1012-1021.
[13] Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol,2018,231:180-187.
[14] 中华医学会妇产科学分会产科学组. 妊娠期肝内胆汁淤积症诊疗指南(2015). 中华妇产科杂志, 2015,50(7):481-485.
[15] 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志,2016,19(6):2-12.
[16] 于乐成,赖荣陶,陈成伟. 2019年欧洲肝病学会临床实践指南_药物性肝损伤_精粹及评析. 临床肝胆病杂志,2019,35(6):1242-1250.
[17] Zhao XJ, Yang YZ, Zheng YJ, et al. Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-κB/NLRP3 inflammasome activation and lipid metabolism disorder. Eur J Pharmacol,2017,809:141-150.
[18] Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr,2002,76(5):1183s-1187s.
[19] Natori S, Fujii Y, Kurosawa H, et al. Prostaglandin E1 protects against ischemia-reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells. Transplantation,1997,64(11):1514-20.
[20] Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholicliver disease. Am J Gastroenterol,2018,113(2):175-194.
[21] Floreani A, Gervasi MT. Newinsights on intrahepatic cholestasis of pregnancy. Clin Liver Dis,2016,20(1):177-189.
[22] 陈鹏,刘兴会,吴琳. 妊娠期肝内胆汁淤积症指南解读. 实用妇产科杂志,2019,35(2):103-105.
[23] Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology,2015,62(2):635-643.
[24] Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab,2005,2(4):217-225.
[25] Poupon R. ASBT inhibitors in cholangiopathies - Good for mice, good for men? J Hepatol,2016,64(3):537-538.
[26] Blank A, Eidam A, Haag M, et al. The NTCP-inhibitormyrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics. Clin Pharmacol Ther,2018,103(2):341-348.
[27] Fickert P, Hirschfield GM, Denk G, et al.Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol,2017,67(3):549-558.
[28] Milkiewicz P, Roma MG, Elias E, et al. Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways. Gut,2002,51(1):113-119.
[29] Chu H, Duan Y, Yang L, et al. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut,2019,68(2):359-370.
[30] Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxincandidalysin promotes alcohol-associated liver disease. J Hepatol,2019[Epub ahead of print].
[31] Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol,2019,70(2):260-272.
[32] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature,2019,575(7783):505-511.

Diagnosis and treatment ofparenchymal jaundice:a type of cholestasis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xiaoxu, Zhang Huajie. Evaluation of fetal cardiac functions by velocity vector imaging in pregnant women with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2020, 23(1): 62-65.
[2]	Chen Huiting, Zhou Yongjian. Diagnosis and management of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2020, 23(1): 153-155.
[3]	Tang Renyi, Hu Qunfeng, Peng Liqing.. Changes of serum lipids, liver function tests and estrogen levels in patients with intrahepatic cholestasis of pregnancy and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(6): 860-863.
[4]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[5]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[6]	Li Qiuxi, Jia Jianfeng, Huang Rui. Efficacy of percutaneous microwave ablation in patients with hepatic cavernous hemangioma and management of hemoglobinuria [J]. Journal of Practical Hepatology, 2019, 22(5): 732-735.
[7]	Yan Lingling, Hu Donghui, Huang Yanfang. Influence of ademetionine combined with polyene phosphatidylcholine on clinical efficacy and laboratory index in patients with intrahepatic cholestasis of pregnancy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 530-533.
[8]	Chen Xiaoqing, Wang Yinchun. Etiology and treatment of intrahepatic cholestatic liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 163-165.
[9]	Xiong Qingfang, Yang Yongfeng. Diagnosis of patients with unknown cause cholestasis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 18-20.
[10]	Sun Lin, Wang Dan, Wu Donghan. Impact of intrahepatic cholestasis of pregnancyon the outcomes of infants [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 133-134.
[11]	Han Yanqing，Ye Piao，Shi Jingyi.. Clinical feature and prognosis of low birth weight infants with cholestasis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 588-591.
[12]	Han Huijuan, Wang Tao. Risk factors of intrahepatic cholestasis of pregnancy in patients with hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 280-283.
[13]	Ke Yingyue，Cui Yingying，Li Quanlun，et al.. Changes of serum biochemical indexes and its impact on perinatal prognosis of neonates in mothers with intrahepatic cholestasis of pregnancy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 187-190.
[14]	Wang Kun， Wang Cuixiu,Wang Xiu.. Comparison of clinical features of neonatal intrahepatic cholestasis and biliary atresia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 228-229.
[15]	Jiang Hao, Ge Hongyan.. Clinical efficacy of ursodeoxycholic acid combined with fat-soluble vitamin in treatment of patients with alcoholic liver disease and intrahepatic cholestasis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 105-106.